Cookies on the
LGC website
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
Question markFind out more

LGC addresses challenge of respiratory product development in successful seminar

17 Oct 2013
Tags:  Pharma

17 October 2013, Fordham, UK – On 3 October, LGC’s Quotient Bio Analytical Sciences hosted a seminar entitled “Respiratory Product Development” at its site in Fordham, Cambridgeshire.

  • This was the 10th annual seminar at the Fordham site and attracted more than 60 delegates from across the pharmaceutical sector. The range of guest speakers who provided stimulating talks of special relevance to this important therapeutic area included:
  • Prof. Tim Higenbottam, Senior Partner, Transcrip Partners, “Regulatory strategies for respiratory product development: opportunities and pitfalls”
  • Dr Tim Noakes, Medical Propellants Business Manager, Mexichem Fluor, “The power inside the world's Metered Dose Inhalers, made in England”
  • Brennan Miles, Senior Consultant, Team Consulting, “Design challenges in inhalation devices”
  • Donna Bennett, Principal Analytical Scientist, Teva Pharmaceuticals, “Extractables and leachables for inhalation devices” 
  • Dr Peter Scholes, Chief Scientific Officer, Quotient Clinical, “New paradigms for expediting PoC in inhaled product development”
  • Gill Mundin, Pharmacokinetics Manager, Mundipharma, “Clinical and PK considerations for respiratory product development”

Dr David Griffiths, Director, Pharmaceutical Services at LGC, said, “Over the last few years, our autumn seminar has focused on a range of different topics of relevance to our services for the pharma sector. This year we chose respiratory product development as a theme because of the important unmet needs across a range of disease types and because it represents some special interesting challenges from the development perspective.  It is also a therapeutic area that spans every part of our pharmaceutical service offering, including aspects of materials science, pharmaceutical analysis, bioanalysis, biomarkers and microbiology.”  Dr Griffiths added that, “We were delighted with the very positive feedback we received from delegates which reinforces our commitment to our annual autumn seminar as we begin to develop ideas for next year’s programme.”

From routine analysis to novel solutions for highly complex challenges, LGC has the scientific experience, technical capability and a proven track record in generating data, providing expert interpretation and answers, overcoming hurdles to accelerate the development of medicines, secure regulatory approval and/or enhance product competitiveness.

To find out more about how LGC can help with respiratory product development, chat to our scientists at booth C1 at the EBF Symposium, Barcelona, 20 - 22 November.

If you would like to know more about LGC’s pharmaceutical services please click here.